Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy

Area of Science:

• Neurology
• Clinical Pharmacology
• Epidemiology

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.
• Riluzole is the only approved medication shown to prolong survival in ALS patients.
• Previous studies on riluzole's efficacy in real-world settings have yielded conflicting results, particularly regarding long-term effects and specific patient subgroups.

Purpose of the Study:

• To evaluate the impact of riluzole on ALS survival in a prospective, population-based cohort.
• To determine if bulbar-onset ALS patients benefit more from riluzole compared to limb-onset patients.
• To assess the effectiveness of riluzole in elderly ALS patients (aged over 70).

Main Methods:

• A prospective, population-based registry of ALS cases in Puglia, Southern Italy, was utilized.
• Survival analysis was performed on 126 incident ALS cases diagnosed between 1998-1999.
• Patients were categorized into those prescribed riluzole (n=73) and those not (n=53), with subgroup analyses based on symptom onset (bulbar vs. limb) and age (>70 years).

Main Results:

• Riluzole therapy increased 12-month survival rates by approximately 10% and prolonged overall survival by a median of 6 months (18.2 vs. 12.4 months).
• A significant survival benefit was observed in bulbar-onset ALS patients (P=0.042) and elderly patients (>70 years), with the latter showing an 8-month longer median survival and a 27% reduction in 12-month mortality.
• No significant survival benefit was found in limb-onset ALS patients. The drug's positive effects on survival were transient, diminishing beyond 12-24 months.

Conclusions:

• Riluzole therapy demonstrates a beneficial effect on ALS survival in a population-based setting, particularly in the early stages of the disease.
• The drug is effective in patients with bulbar-onset ALS and elderly individuals, supporting its use in these specific subgroups.
• The transient nature of riluzole's efficacy highlights the need for further research into optimal treatment duration and potential combination therapies.